Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenus Regulatory News (GNS)

Share Price Information for Genus (GNS)

Share Price is delayed by 15 minutes
Get Live Data
2,198.00    -18.00 (-0.81%)
Bid:
2,188.00
Ask:
2,198.00
Spread: 10.00 (0.457%)
Market Cap: £1.46b
GNS Live PriceLast checked at - London Stock Exchange

Intraday Genus Share Chart

AGM and Interim Management Statement

8 Nov 2012 07:00

RNS Number : 6077Q
Genus PLC
08 November 2012
 



For immediate release

8 November 2012

 

 

Genus plc

('Genus' or 'the Company')

Annual General Meeting ('AGM') and Interim Management Statement

 

At the AGM of Genus to be held at 11.00am today, the following interim management statement will be made for the trading period from 1 July to 31 October 2012.

 

Current Trading

Following last year's record results, revenues for the four months to 31 October 2012 were slightly ahead of the strong performance achieved in the same period last year. Operating profits were lower than the same period last year driven by higher feed costs in our genetic nucleus farms and by delayed sales in Genus ABS caused by adverse weather conditions in Latin America.

 

The overall results have benefited from solid performances in Genus PIC and Genus Asia. In addition the strength of the Genus business model has limited the financial effect on Genus of the higher feed costs that are affecting many of our customers.

 

Genus PIC, comprising the porcine operations in North America, Latin America and Europe, achieved continued volume growth across all three regions. Operating profits were at a similar level to last year despite higher feed costs in our nucleus farm operations and planned increased investment in product development. Performance has benefited from continued growth in the CBV Plus and CBV Max programmes in North America and volume growth in Latin America. Europe has performed ahead of last year reflecting the start of restructuring benefits and the strengthening European porcine market.

 

Genus ABS, comprising the dairy and AI beef businesses in North America, Latin America and Europe, had a slow start to the year. Volumes were lower in Latin America where adverse weather conditions in Argentina and Brazil have caused a delay in semen sales. We expect these sales to be recovered as the year progresses. Performance in North America and Europe was slightly ahead of last year.

 

Genus Asia has had a good start to the year. Revenues and profits were in line with the strong performance achieved in the same period last year.

 

As expected finance costs were higher than last year, reflecting the previously indicated increase in pension interest costs following the additional pension provision made at 30 June 2012.

 

Financial Position

Net debt at the end of October 2012 was at a similar level to end June 2012 and well below the same time last year.

 

Strategy

We have made a good start in implementing our strategy to accelerate the rate of profit growth from 2014 onwards.

 

Following the implementation of a new market-place oriented organisation structure in July 2012, we are establishing global technical services, global marketing and a global supply chain for each of our porcine and dairy/AI beef businesses. This is already starting to create opportunities to enhance customer service which is a key element of our overall growth strategy.

 

In line with our strategy, we have appointed Saskia Korink Romani to the new position of Chief Marketing Officer. Saskia, who joins in January 2013, brings significant international business and marketing experience having worked for 10 years at Cargill, most recently as Vice President of Marketing, Animal Nutrition Division.

 

In Asia, key personnel appointments have been made as part of our plans to ensure we have the right resources in place to meet our growth aspirations.

 

In China, the initial stocking of the Besun porcine joint venture farm has been completed as planned and discussions with other potential joint venture partners are progressing.

 

Outlook

We expect to see a gradual improvement in performance as the year progresses particularly after the slow start in our Genus ABS business. We believe Genus remains on course to achieve another year of growth.

 

With the investments being made in the current year, particularly in emerging markets such as China and in core competencies such as marketing, technical services and product development, the Group is well placed to take advantage of the long-term opportunities available in the global animal genetics market.

 

 

For further information please contact:-

 

Genus plc: Tel: 01256 345970

Karim Bitar, Chief Executive

John Worby, Finance Director

 

 

Buchanan: Tel: 0207 466 5000

Charles Ryland

 

This announcement is available on the Genus website, www.genusplc.com

 

 

About Genus

Genus creates advances to animal breeding and genetic improvement by applying biotechnology and sells added value products for livestock farming and food producers. Its technology is applicable across all livestock species and is currently commercialised by Genus in the dairy, beef and pork food production sectors.

 

Genus' worldwide sales are made in seventy countries under the trademarks "ABS" (dairy and beef cattle) and "PIC" (pigs) and comprise semen and breeding animals with superior genetics to those animals currently in production. Genus' customers' animals produce offspring with greater production efficiency, and quality, and use these to supply the global dairy and meat supply chain.

 

The Group's competitive edge has been created from the ownership and control of proprietary lines of breeding animals, the biotechnology used to improve them and its global supply chain, technical service and sales and distribution network.

 

With headquarters in Basingstoke, United Kingdom, Genus companies operate in thirty countries on six continents, with research laboratories located in Madison, Wisconsin, USA.

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCUBUURURAARUA
Date   Source Headline
9th Jul 20195:12 pmRNSNotification of Major Holdings
3rd Jul 20197:00 amRNSNotification of Major Holdings
1st Jul 20191:45 pmRNSTotal Voting Rights
18th Jun 20193:29 pmRNSNotification of Major Holdings
3rd Jun 20195:43 pmRNSTotal Voting Rights
24th May 20196:03 pmRNSDirector/PDMR Shareholding
16th May 20199:58 amRNSStrategic porcine collaboration in China
1st Apr 20191:54 pmRNSTotal Voting Rights
25th Mar 20197:00 amRNSGenus Chief Executive Transition
4th Mar 20193:11 pmRNSDirector/PDMR Shareholding
1st Mar 20192:00 pmRNSTotal Voting Rights
28th Feb 20197:00 amRNSInterim Results
1st Feb 20192:00 pmRNSBlock listing Interim Review
2nd Jan 20192:49 pmRNSTotal Voting Rights
11th Dec 20181:37 pmRNSDirector/PDMR Shareholding
7th Dec 20187:00 amRNSResult of placing to raise approximately £68m
6th Dec 20184:41 pmRNSProposed placing to raise approximately £68m
21st Nov 201812:00 pmRNSDirector Declaration
15th Nov 20184:00 pmRNSResult of AGM
15th Nov 20187:00 amRNSAGM Trading Update
1st Nov 20182:00 pmRNSTotal Voting Rights
12th Oct 20184:53 pmRNSAnnual Report and Annual General Meeting
12th Oct 20184:37 pmRNSDirector/PDMR Shareholding
12th Oct 20184:37 pmRNSDirector/PDMR Shareholding
1st Oct 20182:00 pmRNSTotal Voting Rights
24th Sep 20186:01 pmRNSAdditional Listing
24th Sep 20181:52 pmRNSNon-Executive Director Retirement
19th Sep 20183:36 pmRNSDirector/PDMR Shareholding
18th Sep 20185:21 pmRNSDirector/PDMR Shareholding
17th Sep 20185:27 pmRNSDirector/PDMR Shareholding
6th Sep 20187:00 amRNSPreliminary Results
1st Aug 20182:00 pmRNSBlock listing Interim Review
20th Jul 201811:56 amRNSHolding(s) in Company
11th Jul 20181:44 pmRNSHolding(s) in Company
9th Jul 20187:00 amRNSHolding(s) in Company
20th Jun 20187:00 amRNSCapital Markets Event
12th Jun 20182:42 pmRNSDirector/PDMR Shareholding
24th May 20187:00 amRNSBoard Appointment
18th May 20185:22 pmRNSDirector/PDMR Shareholding
1st May 20184:39 pmRNSTotal Voting Rights
12th Apr 20186:18 pmRNSDirector/PDMR Shareholding
16th Mar 20182:34 pmRNSDirector/PDMR Shareholding
5th Mar 20186:38 pmRNSDirector/PDMR Shareholding
1st Mar 201810:48 amRNSHolding(s) in Company
28th Feb 20187:00 amRNSInterim Results
1st Feb 20182:00 pmRNSBlock listing Interim Review
29th Dec 201711:51 amRNSDirector/PDMR Shareholding
22nd Dec 201711:27 amRNSDirector/PDMR Shareholding
13th Dec 20175:48 pmRNSDirector/PDMR Shareholding
8th Dec 20174:41 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.